Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori

Launched by KEY LABORATORY FOR GASTROINTESTINAL DISEASES OF GANSU PROVINCE · Feb 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for Helicobacter pylori (H. pylori), a type of bacteria that can cause stomach infections. The researchers want to find out if a medication called Keverprazan, when combined with amoxicillin, is effective in treating people who have just been diagnosed with H. pylori infections for the first time. They will also look at how safe Keverprazan is and whether it causes any side effects. Participants in the trial will take Keverprazan and amoxicillin daily for 14 days and will be monitored for any reactions to the medication. After treatment, they will undergo a breath test to check if the infection has been successfully cleared.

To be eligible for this trial, participants should be between 18 and 65 years old and must have been diagnosed with H. pylori through a breath test. They should not have received any previous treatment for this infection. However, individuals with serious health issues, pregnant or breastfeeding women, and those with certain allergies or recent use of specific medications will not qualify. This trial has not started recruiting participants yet, but it aims to help improve treatments for H. pylori infections in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1)18\~65 years old, gender is not limited;
• • 2) H. pylori infection was diagnosed by urea breath test;
• • 3) Did not receive H. pylori eradication therapy;
• • 4) Informed and consented to participate in this study.
• Exclusion Criteria:
• • 1) Have serious systemic diseases, major organs such as heart, lung, brain diseases, liver and kidney insufficiency, malignant tumors or other diseases;
• • 2) Active peptic ulcer with bleeding, perforation, obstruction, cancer and other complications; And subjects with a past or current history of Zolling-Ellison syndrome's disorders;
• • 3) Allergic history of penicillin and regimen related drugs;
• • 4) Excessive acid-suppressing drugs, such as proton pump inhibitors, potassium competitive acid blockers, histamine H2 receptor antagonists, etc. were used within 2 weeks before enrollment, or antibiotics were used 4 weeks before enrollment;
• • 5) Pregnant or lactating women;
• • 6) Other participants were deemed unsuitable by the researchers.